Xelox (Xeloda + Oxaliplatin) and Avastin for Metastatic Esophagogastric Adenocarcinoma - Related Studies

Xelox (Xeloda + Oxaliplatin) and Avastin for Metastatic Esophagogastric Adenocarcinoma (XAGastric)

This study is currently recruiting participants.

Study NCT00447330. Last updated on August 13, 2008. Information provided by Duke University

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Esophageal Neoplasms
		Stomach Neoplasms
		Neoplasm Metastasis

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Esophageal Diseases
		Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Head and Neck Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplastic Processes
		Pathologic Processes
		Stomach Diseases

4	Additional drug interventions recognized in this trial
		Bevacizumab
		Capecitabine
		Oxaliplatin

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Duke University
		Hoffmann-La Roche
		Sanofi-Aventis
		Genentech